Publications
Evidence that follows the evolving course of disease
Representative figures, study findings, and links to the original papers.
Association between longitudinal weight change and clinical outcome in individuals with MASLD.
Shi Y et al. · Hepatology · 10.1097/HEP.0000000000001557
In a longitudinal cohort of 10,014 people, weight gain above 5% was associated with higher risks of liver-related events and liver-stiffness progression.
Read paperEffect of Antidiabetic Drug Classes on the Risk of Liver-Related Events in Individuals With T2D and MASLD.
Shi Y et al. · Clinical Gastroenterology and Hepatology · 10.1016/j.cgh.2025.06.001
In an observational cohort of 7,867 people across 16 centers, SGLT-2 inhibitor use was associated with lower risks of liver-related events and liver-stiffness progression.
Read paperDissecting the liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure.
Yu X et al.; Shi Y · Hepatology · 10.1097/HEP.0000000000001427
Single-cell and spatial transcriptomics with experimental validation identified the ANXA1–FPR1 resolution axis; Ac2-26 reduced inflammation and liver injury in preclinical models.
Read paperSingle-cell analysis identifies RETN+ monocyte-derived Resistin as a therapeutic target in hepatitis B virus-related acute-on-chronic liver failure.
Xu X et al.; Shi Y · Gut · 10.1136/gutjnl-2025-335998
The study identified an immunoregulatory RETN+ monocyte subset; recombinant Resistin reduced liver injury and inflammation and improved survival in mouse ACLF models.
Read paperClinical, Microbiological, and Antibiotic Treatment Characteristics of Bacterial Infections in Patients with Liver Cirrhosis in China: A Multicenter Study.
Zhang X et al.; Shi Y · Journal of Clinical and Translational Hepatology · 10.14218/JCTH.2025.00211
Across 1,438 patients in 24 Chinese hospitals, 41.0% of isolated organisms were multidrug resistant, supporting region-specific empirical antibiotic strategies.
Read paperValidation of the CLIF-SIG score in patients with HBV-related acutely decompensated cirrhosis.
Chen J et al.; Shi Y · Gut · 10.1136/gutjnl-2025-335810
External validation in HBV-related acute decompensation showed that CLIF-SIG quantifies systemic inflammation and predicts 90-day outcomes and progression to ACLF.
Read paperSex Differences in Risk of Adverse Liver Events in Patients With Cirrhosis.
Shi Y et al. · JAMA Network Open · 10.1001/jamanetworkopen.2025.23674
Among 438,706 people with cirrhosis, men had higher risks of decompensation, hepatocellular carcinoma, and liver transplantation, highlighting sex differences in disease course.
Read paperDifferential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology.
Shi Y et al. · Alimentary Pharmacology & Therapeutics · 10.1111/apt.70059
A cohort of 8,726 people showed that clinical characteristics and survival vary by the underlying cause of cirrhosis and calendar period.
Read paperHepatic and extrahepatic metabolic modulation in HBV-related decompensated cirrhosis and acute-on-chronic liver failure.
Li ZW et al.; Shi Y · Virulence · 10.1080/21505594.2024.2404953
Multi-site serum and liver-tissue omics linked suppressed intrahepatic metabolism and early pro-inflammatory oxylipin changes with systemic inflammation in HBV-ACLF.
Read paperThe clinical courses of HBV-related acute-on-chronic liver failure and a multi-state model to predict disease evolution.
Yu X et al.; Shi Y · Hepatology Communications · 10.1097/HC9.0000000000000354
A multicenter cohort of 445 people mapped reversible HBV-ACLF trajectories; the multistate model reached an AUROC of up to 0.94 for mortality prediction.
Read paperMetabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes.
Zhang Y et al.; Ch-CLIF Consortium · Journal of Hepatology · 10.1016/j.jhep.2023.07.011
Metabolomics and machine-learning models built from 1,024 plasma samples improved early ACLF detection and 90-day prognosis and were translated into LC-MS assays.
Read paperAn ultrasound image-based deep multi-scale texture network for liver fibrosis grading in patients with chronic HBV infection.
Ruan D, Shi Y, Jin L et al. · Liver International · 10.1111/liv.14999
In a multicenter biopsy cohort of 508 people, the ultrasound deep-learning model reached AUCs of 0.92 for significant fibrosis and 0.89 for cirrhosis.
Read paperCirculating Neutrophil Dysfunction in HBV-Related Acute-on-Chronic Liver Failure.
Wu W et al.; Shi Y · Frontiers in Immunology · 10.3389/fimmu.2021.620365
In HBV-ACLF, neutrophil phagocytosis was impaired while NET formation increased, and this dysfunction was associated with adverse outcomes.
Read paperHepatitis B virus persistence and reactivation.
Shi Y, Zheng M · BMJ · 10.1136/bmj.m2200
This State of the Art review synthesizes cccDNA, integrated DNA, host immunity, and HBV reactivation risk across clinical settings.
Read paperRisk stratification of decompensated cirrhosis patients by Chronic Liver Failure Consortium scores: Classification and regression tree analysis.
Shi Y et al. · Hepatology Research · 10.1111/hepr.12751
The study validated CLIF scores in ACLF and non-ACLF decompensated cirrhosis and used classification trees for mortality risk stratification.
Read paperAcute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults.
Shi Y et al. · Hepatology · 10.1002/hep.27795
Among 1,361 people with decompensated cirrhosis, 405 ACLF cases showed distinct organ-failure patterns and outcomes for hepatic versus extrahepatic precipitants.
Read paper